Detail

Basic Information Clinical Results Relationship Graph

Basic Information

Gene symbol	S	Synonyms	E2	Type of gene	protein-coding
Chromosome	-	Map location	NC_004718.3 (21492..25259)	dbXrefs
Gene perturbation-related omics dataset	PerturbAtlas
Description	spike glycoprotein

GTO ID	GTC0552
Trial ID	NCT04952402
Disease	COVID-19
Altered gene	S
Therapeutic/Target gene	Therapeutic gene
Therapy	mRNA vaccine
Treatment	mRNA-1273\|Elasomeran\|Spikevax;BNT162b2\|COMIRNATY\|Tozinameran
Co-treatment	AZD7442\|BRII-196\|BRII 198\|SAB 185\|BMS 096414\|BMS 986413
Location approved	UK, Canada, China, Switzerland, Japan, EU, Australia, South Korea, Singapore, US;UK, Bahrain, Israel, Canada, US, Rwanda, Serbia, United Arab Emirates, China, Mexico, Kuwait, Singapore, Saudi Arabia, Chile, Switzerland, EU, Ghana, Colombia, Philippines, Indonesia, Australia, Peru, South Korea, New Zealand, Japan, Brazil, Sri Lanka, Vietnam, South Africa, Thailand, Oman, Egypt, Malaysia
Phase	Phase4
Recruitment status	Completed
Title	SARS-CoV-2 Immune Responses After COVID-19 Therapy and Subsequent Vaccine
Year	2021
Country	United States
Company sponsor	National Institute of Allergy and Infectious Diseases (NIAID)
Other ID(s)	A5404

Vector information

Vector	lipid nanoparticle

Clinical Result

Cohort1: AZD7442_BRII-196_BRII 198_SAB 185_BMS 096414_BMS 986413

Administration route	intramuscular injection\|subcutaneous injection
Dosage	mRNA-1273, 100 µg (0.5 mL), at Day 0 and Day 28; BNT162b2, two dose
Pts	8
Age	Adult, Older_Adult
Outcome	Neutralizing Antibody (NAb) Level:50% neutralizing dilution titers (ND50):2242.47(688.55 to 7303.29); 80% neutralizing dilution titers (ND80):888.80(222.60 to 3548.78)
Adverse reactions	No serious clinical adverse events

Cohort2: Placebo

Administration route	intramuscular injection
Dosage	mRNA-1273, 100 µg (0.5 mL), at Day 0 and Day 28; BNT162b2, two dose
Pts	10
Age	Adult, Older_Adult
Outcome	Neutralizing Antibody (NAb) Level:50% neutralizing dilution titers (ND50):2695.21(1005.71 to 7222.88); 80% neutralizing dilution titers (ND80):972.43(358.67 to 2636.46)
Adverse reactions	No serious clinical adverse events

Cohort3: mRNA-1273

Administration route	intramuscular injection
Dosage	mRNA-1273, 100 µg (0.5 mL), at Day 0 and Day 28; BNT162b2, two dose
Pts	24
Age	Adult, Older_Adult
Outcome	Neutralizing Antibody (NAb) Level:50% neutralizing dilution titers (ND50):2196.74(970.88 to 4970.42); 80% neutralizing dilution titers (ND80):794.90(364.34 to 1734.27)
Adverse reactions	No serious clinical adverse events

Relationship Graph

Overview of Knowledge Graph